TCTMD’s Top 10 Most Popular News Stories for 2010

The most popular news stories that appeared on TCTMD in 2010 provide a snapshot of the year in interventional cardiology with a strong focus on stenting and adjunct pharmacology. Below are the 10 most read stories from the past year in descending order. Interestingly, the most popular story was dissimilar from the rest, describing a novel vascular access technology.

1. From TCT 2010: Vascular Access Device Achieves Low Complication Rates

WASHINGTON, DC—A novel vascular access device produces acceptable compression times and low complication rates, according to a first-in-man study of over 1,000 patients. The product is intended to facilitate access to the common femoral artery and to achieve hemostasis without the use of a closure device. (Read more…)

2. From JACC: Cardiovascular Interventions: FFR Guidance for Questionable Lesions Dramatically Cuts Stenting vs. IVUS

Physiological assessment of intermediate lesions with fractional flow reserve (FFR) reduces percutaneous coronary interventions by two thirds compared with intravascular ultrasound (IVUS) evaluation, according to a retrospective study published in the August 2010 issue of JACC: Cardiovascular Interventions. (Read more…)

3. From AHA 2010: Final Results Provide CLOSURE on Device Therapy for PFOs, Cryptogenic Stroke

CHICAGO, IL—While the announcement that CLOSURE I failed to achieve its primary endpoint came months ago on June 17, 2010, the full results of the randomized study were not formally released until Monday, November 15 at the American Heart Association Scientific Sessions 2010. The findings provide even stronger evidence that percutaneous device closure lacks superiority over medical therapy alone in preventing recurrent stroke and mortality in patients with patent foramen ovale (PFO). (Read more…)

4. From ACC/i2 2010: Studies Compare Multiple Drug-Eluting Stents

ATLANTA, GA—Two late-breaking clinical trials presented Monday, March 15, 2010, at the ACC/i2 Summit show mixed results for Endeavor when tested against a first-generation and a next-generation drug-eluting stent (DES). In SORT OUT III, Endeavor continued to lag behind Cypher at 18 months, with the exception of cardiac death and Academic Research Consortium-defined definite stent thrombosis. The ISAR-TEST-2 trial, meanwhile, showed durable results at 2 years for both Endeavor and a polymer-free sirolimus- and probucol-eluting stent referred to as Dual DES. (Read more…)

5. From JACC: IVUS Offers Insights into Very Late Stent Thrombosis with DES, BMS

IVUS findings suggest that very late stent thrombosis may arise by different mechanisms. Disease progression culminating in neointimal or plaque rupture is associated with the event in both DES and bare metal stents (BMS), while stent malapposition is typically found only in DES thrombosis. The findings appear in a study published in the May 4, 2010, issue of the Journal of the American College of Cardiology. (Read more…)

6. From TCT 2010: SPIRIT III: Everolimus-Eluting Stent Safety, Efficacy Maintained at Four-Year Follow-Up

WASHINGTON, DC—The use of everolimus-eluting stents compared with paclitaxel-eluting stents resulted in significantly reduced rates of the composite safety and efficacy measures of target lesion failure (TLF) and major adverse cardiac events (MACE), according to four-year data from the SPIRIT III trial presented at TCT 2010. In addition, there was no evidence of late catch-up in target lesion revascularization (TLR). (Read more…)

7. From ACC/i2 2010: Extending Clopidogrel Beyond 12 Months Not Supported

ATLANTA, GA—Use of dual antiplatelet therapy after implantation of a DES for longer than 12 months does not reduce rates of myocardial infarction (MI) or cardiac death more than aspirin monotherapy, according to late-breaking trial results presented Monday, March 15, 2010, at the annual American College of Cardiology Scientific Session/i2 Summit. (Read more…)

8. From TCT 2010: SYNTAX at 3 Years: PCI Matches CABG in Left Main Disease

WASHINGTON, DC—New results from the SYNTAX trial showed that patients with three-vessel disease derive less benefit from PCI than from CABG at 3 years. But in left main disease patients, both treatments remain equally safe and effective over the same period, according to 2 clinical trial presentations at TCT 2010. (Read more…)

9. From TCT 2010: HORIZONS-AMI at 3 Years: Taxus, Bivalirudin Hold Their Lead

WASHINGTON, DC—At 3 years, STEMI patients who underwent PCI with bivalirudin and paclitaxel-eluting stents continue to fare best over the long-term compared with those receiving heparin plus a glycoprotein IIb/IIIa inhibitor and a BMS, according to late-breaking results from HORIZONS-AMI. (Read more…)

10. From JACC: Selective In-Lab Clopidogrel a Safe Alternative to Pretreatment

Giving patients a 600-mg loading dose of clopidogrel in the cath lab after diagnostic angiography to establish the need for PCI yields outcomes comparable to routine preloading, according to a study published in the August 10, 2010, issue of the Journal of the American College of Cardiology. The wait-and-see approach to clopidogrel administration avoids unnecessary bleeding risk in patients for whom bypass surgery or medical therapy is deemed more appropriate than PCI. (Read more…)

 

Related Stories:

Jason R. Kahn, the former News Editor of TCTMD, worked at CRF for 11 years until his death in 2014…

Read Full Bio

Comments